BAT's BTV Launches Second Fund Focused on Health and Innovation

BAT by 2FIRSTS.ai
Dec.19.2024
BAT's BTV Launches Second Fund Focused on Health and Innovation
BAT's Btomorrow Ventures launches second fund with focus on health and innovation, demonstrating commitment to smoke-free world.

On December 18, British American Tobacco (BAT) announced on its official website that its venture capital arm, Btomorrow Ventures (BTV), has launched its second fund. The fund will mainly focus on health and wellness businesses, in line with BAT's strategic exploration of non-nicotine products. The launch of the new fund comes with an additional commitment of £200 million in investments, showcasing BAT's dedication to creating a "smoke-free world.

 

The Business Development Director of BAT, James Barrett, stated,

 

The launch of the second fund is an important demonstration of BAT's confidence in BTV as a key part of BAT's transformation agenda, which aims to turn BAT into a diversified consumer goods business. By focusing on health and innovation investments, we are committed to advancing BAT's smoke-free world agenda, building on the success of BTV's first fund.

 

Since its first investment in 2020, BTV's first fund has made 28 investments, primarily focusing on early-stage financing to support companies developing innovative products that align with the vision of creating a smoke-free world with BAT, and to reduce risk in new product categories.

 

Most of the initial £150 million fund has already been deployed or committed, including investments in the American functional beverage brand Moment and the Canadian caffeinated chocolate brand AWAKE.

 

The second fund is a supplement to the BTV Impact program launched earlier this year, which aims to harness the power of the venture capital community to support and advance its sustainability, diversity, and inclusivity agendas.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
The EU’s consultation on the Cardiovascular Health Plan, though not mentioning nicotine, has sparked debate over novel tobacco regulation. Advocates urge evidence-based recognition of harm reduction products, while opponents call for tighter rules. The plan may influence TPD III, drawing close scrutiny from both industry and health groups.
Sep.01
Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways
Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways
2Firsts analyzes vaping regulations across the Baltic states. Following Latvia’s flavor ban, tax revenues fell and the black market expanded, while similar measures in Estonia and Lithuania have also failed to deliver results. The region’s anti-vaping policies are now triggering market imbalance and policy reassessment.
Oct.13
Expo Preview | Century-old Hong Kong Nanyang Brothers Tobacco Co., Ltd Debuts in Next-Gen Tobacco? Sneak Peek from the Exhibition Hall
Expo Preview | Century-old Hong Kong Nanyang Brothers Tobacco Co., Ltd Debuts in Next-Gen Tobacco? Sneak Peek from the Exhibition Hall
On the eve of Inter Tabac 2025, 2Firsts noticed the presence of Hong Kong Nanyang Brothers Tobacco, a company with over a century of history, at the exhibition venue. Based on booth preparations, the company is expected to unveil a range of new products, including e-cigarettes, NicPouch Strip, Heat Not Burn(HNB), and wellness-related offerings. More details will be revealed on September 18.
Sep.17
RELX Deepens UK Market Strategy: Appoints Chill Brands as Key Distribution Partner Following Major Retail Acquisition
RELX Deepens UK Market Strategy: Appoints Chill Brands as Key Distribution Partner Following Major Retail Acquisition
RELX International has appointed Chill Brands Group Plc (LSE: CHLL) as its primary UK distribution partner for the MaxGo series, with first shipments due in September 2025. The partnership, executed via the Chill Connect sales team, follows RELX’s acquisition of retailer Totally Wicked, highlighting its accelerated UK market expansion.
Sep.02
Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
At the inaugural AFN, Dr. Rohan Sequeira and Dr. Alex Wodak emphasized that THR offers a science-based approach to reduce smoking-related harm—not merely as an alternative to cessation. They urged policymakers across Asia to reassess tobacco control and include non-combustible products in public health strategies. This article outlines the scientific foundation of THR, its regional challenges, and growth momentum.2Firsts provided in-depth coverage of the forum.
Sep.09
Pakistan Government Moves to Make Smokeless Tobacco Nicotine Products Mandatory Standards

The Pakistan government has instructed the Ministry of Science and Technology (MoST) and the Pakistan Standards and Quality Control Authority (PSQCA) to accelerate
Pakistan Government Moves to Make Smokeless Tobacco Nicotine Products Mandatory Standards The Pakistan government has instructed the Ministry of Science and Technology (MoST) and the Pakistan Standards and Quality Control Authority (PSQCA) to accelerate
Pakistan government instructs MoST and PSQCA to include smokeless tobacco products in mandatory standards, aiming to boost exports and curb illegal products.
Aug.26 by 2FIRSTS.ai